November 16, 2019 Regulatory LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
November 7, 2019 Regulatory LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China
October 23, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year
September 24, 2019 Regulatory Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect
May 6, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals
May 2, 2019 Regulatory LIDDS develops its own proprietary product for intratumoral immunotherapy – Freedom to operate analysis done for the TLR9-agonist project
April 2, 2019 Regulatory LIDDS announces a novel TLR9 agonist project and plan for Phase I clinical trial
March 18, 2019 Regulatory LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020